NCT04636814 · Interventional trial
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
Overall registry status Terminated
Phase 3
Conditions Chronic Obstructive Pulmonary Disease
Delaware Valley sites
- Chiesi Clinical Trial - Site 840671 · Philadelphia, PA · Philadelphia County
- Chiesi Clinical Trial - Site 840683 · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory